Business
Notice of AGM
Convatec Group Plc has announced its Annual General Meeting will be held on Thursday, 21 May 2026, at 14:00 UK time. The Notice of Annual General Meeting and Form of Proxy are being sent to shareholders and have been submitted to the National Storage Mechanism. The company, which reported revenues exceeding $2 billion in 2025, is a global medical products and technologies company focused on chronic condition management. Disclaimer*
About this update from Convatec Group Plc
17 March 2026 Convatec Group Plc ("Convatec" or "the Company") Notice of Annual General Meeting The Company's annual general meeting (the "Annual General Meeting") will take place at 14:00 (UK time) on Thursday 21 May 2026 at the Company's offices at 20 Eastbourne Terrace, London W2 6LG. The Company's Notice of Annual General Meeting and Form of Proxy including details of how shareholders can appoint a proxy, are being sent to shareholders today and have been submitted to the National Storage Mechanism in accordance with UK Listing Rule 6.4.1 of the Financial Conduct Authority. These documents will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism . A copy of the Company's Notice of Annual General Meeting can be accessed on the Company's website at www.convatecgroup.com . This announcement is made in accordance with DTR 6.3.5R(1A). Enquiries James Kerton, Company Secretary Email: [email protected] Convatec Group Plc's LEI code is 213800LS272L4FIDOH92 Classification: 3.1 Additional regulated information required to be disclosed under the laws of the United Kingdom About Convatec Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
View stock analysis, news, and events for Convatec Group Plc